AbbVie pays $100M upfront for the IBD drug Nxera shelved a year ago

A year ago, Nxera Pharma deprioritised its EP4 agonist as part of a restructuring. This week AbbVie paid $100 million upfront for it. Nxera announced the global licence on 4 November, giving AbbVie worldwide rights to develop and sell NXE0033744 in inflammatory bowel disease.

The terms

AbbVie pays $100 million upfront, with up to $1.37 billion more in development and commercial milestones and tiered royalties on sales. BioSpace puts the total at up to $1.47 billion. The deal still needs antitrust clearance, including under the Hart-Scott-Rodino Act, and Nxera expects to book the upfront as revenue in the fourth quarter.

Get Tx Weekly every TuesdayThree-minute read. Free. One-click unsubscribe.

A different way into IBD

Most IBD drugs, from TNF blockers to IL-23 antibodies, work by damping the immune system. NXE0033744 is an oral small molecule that activates the EP4 receptor and is designed to stay in the gut, keeping systemic exposure low. Jefferies analysts told BioSpace its mechanism "differs from existing drugs that target the immune system" and that they expect it to be used mostly in combination.

The Phase 1 programme is done. It covered single and multiple ascending doses, a cohort of ulcerative colitis patients and an indomethacin challenge cohort, where Nxera says the drug reduced indomethacin-induced intestinal permeability with no adverse events of concern.

Old partners

This is the third tie-up between the two companies. BioSpace notes a 2020 inflammation and autoimmune deal worth up to $409 million and a 2022 neuroscience collaboration that could reach $1.3 billion. The asset came from Nxera's NxWave discovery platform.

"this agreement is a strong vote of confidence in NxWave's ability to consistently deliver." Christopher Cargill, President and CEO, Nxera Pharma

For Nxera, which cut 15% of its workforce in Japan and the UK in its November 2025 restructuring, the money matters. It has nudged its full-year revenue forecast to the top of its range, 48.8 billion yen ($307.9 million), and will keep its own pipeline focused on obesity, metabolic and endocrine disease.

The bigger picture

AbbVie told investors last week it prefers bolt-on deals in its core areas, and this is a textbook one. BioSpace notes the drug could build on Skyrizi and Rinvoq, possibly in combination. Adding a non-immune oral mechanism looks like a bet on combinations, the same thinking behind Gilead's plan for an all-oral IBD regimen. Expect more of these: big I&I franchises shopping for mid-sized, cleanly de-risked assets they can pair with what they already sell.

What it means for hiring

Combination strategies in IBD need clinical and translational leaders who can design trials around two mechanisms at once. That's a rare skill set, and AbbVie won't be the only company looking for it.
Licensing deals for shelved assets show the value of a strong BD and alliance team on the out-licensing side. Smaller companies with platforms like NxWave need commercial BD leaders who can keep partners coming back.
Gut-restricted small molecules lean heavily on clinical pharmacology and GI-specialist medical teams as they move into Phase 2.

Share Ask Harry about this →